8-K: NovaBay Secures $6M Investment, Shifts Strategy

NovaBay Pharmaceuticals has secured a $6 million investment from David E. Lazar, appointing him CEO and pivoting from potential liquidation to a new strategic acquisition path, alongside a planned special cash dividend for stockholders.

Summary

• NovaBay Pharmaceuticals entered a $6.0 million securities purchase agreement with investor David E. Lazar.
• The company received an initial $3.85 million for 481,250 shares of Series D non-voting convertible preferred stock, with a second closing of $2.15 million for 268,750 shares of Series E non-voting convertible preferred stock contingent on stockholder approval.
• Each share of Series D and Series E preferred stock is convertible into 160 shares of common stock, totaling 77.0 million and 43.0 million common shares respectively upon full conversion.
• The company plans to declare a special cash dividend to stockholders in the fourth quarter of 2025, expected to be at least $0.80 per share, totaling approximately $4.66 million based on 5,823,497 common shares outstanding as of August 12, 2025.
• Three largest Series F-1 warrant holders exchanged 1,986,565 warrants for new Series F voting retractable preferred stock and an aggregate cash payment of $525,000 ($175,000 per holder).
• A voting agreement was established with Jad Fakhry and Poplar Entities, representing approximately 17.54% of outstanding common stock, committing them to vote in favor of key proposals, including the investment and share increases.

Sentiment

Score: 8

Explanation: The filing indicates a significant positive shift for NovaBay, moving from potential liquidation to a recapitalization and strategic pivot. The substantial investment, planned special dividend, and new leadership provide a clear path forward and immediate value to shareholders, despite potential future dilution and the need for stockholder approvals.

Positives

• Secured $6.0 million in new capital, providing liquidity and funding for future operations and strategic initiatives.
• Avoided potential voluntary liquidation and dissolution, maintaining public listing on NYSE American.
• Planned special cash dividend of at least $0.80 per share for stockholders, providing immediate return of capital.
• Resolution of significant outstanding warrants through exchange for preferred stock and cash, reducing potential future dilution from warrant exercises.
• New CEO David E. Lazar brings experience in capital restructuring and public company investments, potentially enhancing strategic direction.
• Commitment from new investor David E. Lazar to ensure sufficient capital for a Post-Investment Transaction and 12 months of target company operations.

Negatives

• Significant potential dilution for existing common stockholders upon full conversion of Series D and E preferred stock, which could represent over 90% of fully diluted common stock.
• Conversion of preferred stock is contingent on stockholder approval, introducing uncertainty and potential delays.
• The special dividend amount is "expected" and subject to the independent Special Transaction Committee's direction, not a guaranteed fixed amount.
• The company's ability to regain compliance with NYSE American listing requirements is subject to risks.
• The "full-ratchet anti-dilution protection" for Series D and E preferred stock could further dilute common stockholders if future equity is issued at a pre-money imputed equity value less than $10.0 million, unless stockholder approval is required.

Risks

• Failure to obtain stockholder approval for the conversion of Series D and E preferred stock, the increase in authorized common and preferred shares, the increase in the equity incentive plan, the issuance of equity consideration to directors, and the reverse stock split.
• Potential trading suspension of the Common Stock by the SEC or NYSE American.
• Uncertainty regarding the successful identification, due diligence, and completion of a Post-Investment Transaction.
• Risks related to the company's business as detailed in its latest Form 10-K, subsequent Forms 10-Q, and Form 8-K filings under the "Risk Factors" heading.
• Forward-looking statements are subject to known and unknown risks, uncertainties, and other factors that may cause actual results to differ materially.
• The company's ability to regain compliance with NYSE American listing requirements is not guaranteed.

Future Outlook

NovaBay Pharmaceuticals intends to use the proceeds from the investment to pursue a strategic investment and/or acquisition of an operating going concern and solvent company (Post-Investment Transaction) by the end of Q3 2025 (if stockholder approval is obtained) or by the end of Q4 2025. The company also expects to declare a special cash dividend to stockholders in the fourth quarter of 2025. Future actions include holding an annual meeting in Q4 2025 to seek stockholder approval for key proposals, including preferred stock conversion, increased authorized shares, director elections, and a reverse stock split.

Management Comments

• "In making this significant investment in NovaBay, I look forward to maintaining NovaBay’s public listing and actively exploring strategic opportunities to drive value for our stockholders." David E. Lazar, new CEO.
• "I appreciate the NovaBay Board’s unanimous support for this transaction and faith in my ability to widen the Company’s path towards strategic alternatives." David E. Lazar, new CEO.
• "David brings to NovaBay significant capital restructuring and reverse merger expertise, and I look forward to working with him to identify business opportunities and strategic alternatives that could be transformative for NovaBay." Justin Hall, former CEO.
• "Following our Board’s careful review of strategic options, we view this transaction with Mr. Lazar as the best path forward for our stockholders." Justin Hall, former CEO.

Industry Context

This announcement reflects a broader trend among smaller publicly traded companies, particularly those that have divested core assets, to seek strategic alternatives such as reverse mergers or significant new investments to avoid liquidation and potentially pivot into new business areas. The involvement of an investor with 'capital restructuring and reverse merger expertise' suggests a strategy to leverage the existing public listing for a new operating business, a common approach for 'shell' companies or those undergoing significant transformation.

Management Changes

Corporate Governance

Related Party Transactions

• Securities Purchase Agreement with David E. Lazar (new CEO and Director).
• Warrant Exchange Agreements with Armistice Capital, LLC (whose CIO, Steven Boyd, signed the agreement, indicating a significant institutional holder).
• Voting Agreement with Jad Fakhry and Poplar Entities (significant stockholder group).
• Employment agreements and settlement/release agreements with current and former executives (Justin Hall, Tommy Law) and resigning non-employee directors.

Stakeholder Impact

• Shareholders: Potential for a special cash dividend ($0.80/share expected) and avoidance of company liquidation. However, significant potential dilution from preferred stock conversion (over 90% on a fully diluted basis) and a reverse stock split are planned, which could negatively impact per-share value.
• Employees: Changes in executive leadership (new CEO, new CFO, former CEO in new role). New employment agreements for key personnel.
• Warrant Holders: Three largest warrant holders exchanged their warrants for new preferred stock and cash, resolving their outstanding instruments.
• Company Operations: Influx of $6.0 million capital to fund ongoing operations and pursue a new strategic investment/acquisition, providing a new business direction.

Next Steps

• Company to file a Current Report on Form 8-K disclosing material terms of the transactions.
• Company to hold its 2025 Annual Meeting of Stockholders in Q4 2025 to obtain stockholder approval for: conversion of Series D and E Preferred Stock into Common Stock, increase in authorized Common Stock to 300 million shares, increase in authorized preferred stock to 10 million shares, election of Company directors (including David Lazar's nominees), increase in shares available under the 2017 Omnibus Incentive Plan to 1 million shares, issuance of Equity Consideration to Resigning Non-Employee Directors, and a reverse stock split (1-for-2 to 1-for-10 range).
• Company to declare and pay a special cash dividend to stockholders in Q4 2025.
• Company to pursue a strategic investment and/or acquisition of an operating going concern and solvent company (Post-Investment Transaction) by the end of Q3 2025 (if stockholder approval is obtained) or by the end of Q4 2025.
• Final Closing of the investment (receipt of $2.15 million) to occur after stockholder approval.
• Resigning non-employee directors to resign from the Board after Conversion Approval, Final Closing, and appointment of Additional Purchaser Nominees.
• Series F Preferred Stock holders may request retirement of their shares after Stockholder Approval or December 31, 2025.

Key Dates

Recommendation

The filing presents a complex situation with both significant upside and considerable risks. The $6 million investment and planned special dividend offer immediate positive catalysts, potentially preventing liquidation and providing a return to shareholders. However, the substantial potential dilution from the preferred stock conversion (over 90% on a fully diluted basis) and the planned reverse stock split introduce significant uncertainty regarding future per-share value. While the strategic pivot and new leadership are positive, the success of the 'Post-Investment Transaction' is speculative. Investors should 'hold' to observe the outcome of the stockholder approvals, the actual dividend payment, and the clarity of the new strategic direction before making further investment decisions.

Keywords

NovaBay Pharmaceuticals, NBY, SEC Filing, 8-K, Preferred Stock, Warrant Exchange, Special Dividend, David Lazar, Strategic Investment, Corporate Governance, Management Change, Capital Raise, NYSE American, Dilution, Shareholder Approval